ReviewBiomedicines2024
Endometrial Cancer in Reproductive-Aged Females: Etiology and Pathogenesis.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Insights and limitations of endometrial cancer risk prediction models for clinical applicability: a systematic review.BMC cancer · 2025Pooled it
- Single-nuclei RNA sequencing reveals obesity-associated rewiring of estrogen signaling in endometrioid adenocarcinoma.iScience · 2026Article
- Molecular Classification of Endometrial Cancer in the Era of Precision Oncology: Prognostic Significance, Emerging Biomarkers, and Personalized Therapeutic Strategies-A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Response to progestin-based therapy in endometrial intraepithelial neoplasia: An exploratory biomarker study.Gynecologic oncology reports · 2026Article
- Comparative prognostic performance of International Federation of Gynecology and Obstetrics 2023 staging system and the 2025 European Society of Gynaecological Oncology-European Society for Radiotherapy and Oncology-European Society of Pathology risk classification in endometrial cancer.Obstetrics & gynecology science · 2026Article
- Diagnostic accuracy of the droplet digital PCR POLE mutation test in endometrial cancer: comparison with Sanger sequencing and NGS.Journal of gynecologic oncology · 2026Article
- Screening for endometrial hyperplasia and endometrial cancer in premenopausal women withBMJ open · 2026Article
- A Retrospective Cohort Study of Uterine Cancer Epidemiological Analysis and Age-Based Disparities in Saudi Arabian Population across 32 Years.Saudi medical journal · 2026Article
- A Review of the Potential Therapeutic Benefits of Quercetin for Uterine-Related Conditions.Biomedicines · 2026Review
- Global trends in fertility-preserving treatment for endometrial cancer: a bibliometric analysis, 2005-2024.Discover oncology · 2026Article
- Article
- Impact of hypothyroidism and hyperthyroidism on endometrial cancer incidence: results from a large population-based cohort study.European journal of epidemiology · 2026Article
- Endometrial cancer awareness as a public health blind spot: a cross-sectional survey study.BMC public health · 2026Article
- Cytostatic and Non-Apoptotic Effects of Vinorelbine-Based Therapy in 3D Endometrial Cancer Spheroids.Biology · 2026Article
- Impact of the 2023 FIGO staging revision on MRI diagnostic accuracy in FIGO 2009 stage I endometrial cancer.Abdominal radiology (New York) · 2026Article
- Feasibility ofCancers · 2026Article
- Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers.Communications medicine · 2026Article
- The quality and reliability of endometrial cancer-related videos on social short video platforms: a cross-sectional study.BMC women's health · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is the most common gynecologic malignancy in developed countries, and the incidence is rising in premenopausal females. Type I EC is more common than Type II EC (80% vs. 20%) and is associated with a hyperestrogenic state. Estrogen unopposed by progesterone is considered to be the main driving factor in the pathogenesis of EC. Studies show that BMI > 30 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.